AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $221.79, giving the company a market capitalization of 391.86B. It carries a P/E multiple of 109.29 and pays a dividend yield of 3.04%.
As of 2026-06-16, AbbVie(ABBV) stock has fluctuated between $219.15 and $223.37. The current price stands at $221.79, placing the stock +1.2% above today's low and -0.7% off the high.
The AbbVie(ABBV)'s current trading volume is 2.18M, compared to an average daily volume of 5.18M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.
ABBV News
...
Allergan Aesthetics, an AbbVie (ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines for the improvement of neck appearan...
Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years By Drew Wood Published Jun 13, 8:02AM EDT Quick Read A $686,000...
Analyst ratings
73%
of 33 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is launching a new early-stage trial focused on children with hard-to-treat ac...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie’s new study, officially titled “Phase 2/3 Open Label Randomized Study of Telisotuzuma...
The company unveiled results from the Phase 3 CLL14 trial involving its venetoclax-based therapy for chronic lymphocytic leukemia (CLL). New Venetoclax Data At...
Key Points The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs. Long-term cash flow gro...
In recent days, AbbVie has reported new hematology data at the EHA 2026 Congress, advanced its CLL and migraine portfolios in Europe, and managed smaller regula...
AbbVie (ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association, or EHA, 2026 Congress taking p...
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225 By Alex Sirois Published Jun 11, 2:22PM EDT Quick Read ABBV surged 54% from its 20...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.